PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
EBIT growth above 1.5x TRVN's 11.33%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.68%
Operating income growth above 1.5x TRVN's 11.33%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
22.99%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
38.32%
EPS growth above 1.5x TRVN's 4.30%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
38.32%
Diluted EPS growth above 1.5x TRVN's 4.30%. David Dodd would see if there's a robust moat protecting these shareholder gains.
24.80%
Share count expansion well above TRVN's 7.90%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.80%
Diluted share count expanding well above TRVN's 7.90%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.87%
OCF growth under 50% of TRVN's 48.71%. Michael Burry might suspect questionable revenue recognition or rising costs.
22.60%
FCF growth under 50% of TRVN's 49.38%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Negative 10Y OCF/share CAGR while TRVN stands at 75.41%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
19.53%
Below 50% of TRVN's 75.41%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
73.45%
3Y OCF/share CAGR similar to TRVN's 69.48%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-5088.50%
Negative 10Y net income/share CAGR while TRVN is at 60.73%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.11%
5Y net income/share CAGR similar to TRVN's 60.73%. Walter Schloss might see both on parallel mid-term trajectories.
78.36%
3Y net income/share CAGR 1.25-1.5x TRVN's 52.68%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
2877.65%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
75.50%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-75.29%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Negative asset growth while TRVN invests at 5.37%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-36.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Our R&D shrinks while TRVN invests at 11.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-16.18%
We cut SG&A while TRVN invests at 16.84%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.